Ocugen, Inc.
Bioscience Park Center
12635 E Montview Boulevard
Aurora
Colorado
80045
United States
Tel: 720-859-3549
Website: http://ocugen.com/
159 articles with Ocugen, Inc.
-
Ocugen Provides Business Update and First Quarter 2022 Financial Results
5/6/2022
Ocugen, Inc. reported first quarter 2022 financial results along with a general business update.
-
Ocugen to Host Conference Call on Friday, May 6 at 8:30 a.m. ET to Provide Business Update and Discuss First Quarter 2022 Financial Results
5/2/2022
Ocugen, Inc. today announced that it will host a conference call to provide a business update and discuss its first quarter 2022 financial results at 8:30 a.m. ET on Friday, May 6, 2022.
-
A roundup of last week's top clinical trial updates and news.
-
Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
4/29/2022
Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing and commercializing novel gene therapies, biologicals and vaccines, today announced two presentations on the company’s research into the development of a modifier gene therapy to treat dry age-related macular degeneration (AMD), and a novel biologic to treat wet-AMD and diabetic macular edema (DME) at The Association for Research in Vision and Ophthalmology’s (ARVO) 2022 Annual Meeting.
-
The DSMB for Ocugen's Phase I/II trial of OCU400, a gene therapy in development for Retinitis Pigmentosa (RP), recommended the study proceed with enrolling more patients.
-
Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial
4/25/2022
Ocugen, Inc. announced today that the independent Data and Safety Monitoring Board (DSMB) for its Phase 1/2 clinical trial of OCU400 reviewed safety data based on dosing to date and recommended that the study proceed with enrolling additional subjects.
-
Ocugen, Inc. to Present at NobleCon18
4/19/2022
Ocugen, Inc. announces that Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen, will present on-location at NobleCon18 - Noble Capital Markets’ Eighteenth Annual Investor Conference.
-
Ocugen has amended its co-development, supply and commercialization deal with Bharat to include Mexico and now holds the rights for the Covaxin vaccine for all of North America.
-
Ocugen, Inc. to Commercialize COVAXIN™ in Mexico, Rights Now Encompassing All of North America
4/18/2022
Ocugen, Inc. today announced that they have entered into an amendment to their Co-development, Supply and Commercialization Agreement to expand Ocugen’s exclusive territory to include commercialization of COVAXIN™ in Mexico.
-
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
-
Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™ (BBV152)
4/12/2022
Ocugen, Inc. announced that the Company was informed by the U.S. Food and Drug Administration (FDA) that the agency placed its Phase 2/3 immuno-bridging and broadening study for COVAXIN™ (BBV152), OCU-002, on clinical hold.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration
4/1/2022
Ocugen, Inc. announced that the first patient has been dosed in the Phase 1/2 clinical trial of OCU400.
-
BioSpace Movers & Shakers, March 25
3/25/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Ocugen Announces Appointment of Marna C. Whittington, PhD, to Board of Directors
3/23/2022
Ocugen, Inc. today announced the appointment of Marna C. Whittington, PhD, to the Board of Directors. Her term became effective March 21, 2022.
-
Ocugen, Inc. Appoints Jessica Crespo, CPA, to Chief Accounting Officer and Senior Vice President, Finance
3/21/2022
Ocugen, Inc. today announced the appointment of Jessica Crespo, CPA, as Chief Accounting Officer and Senior Vice President, Finance.
-
Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/18/2022
Ocugen, Inc. today announced the Compensation Committee of the Board of Directors of Ocugen approved the grant of stock options to purchase an aggregate of 331,155 shares of its common stock.
-
Ocugen, Inc. to Present at the 34th Annual ROTH Conference
3/9/2022
Ocugen, Inc. today announces that Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen, Inc., will be presenting at the 34th Annual Roth Conference.
-
The biopharma industry ended February and began March with plenty of clinical trial news. BioSpace shares the highlights.
-
Ocugen Provides an Update on its COVAXIN™ Pediatric (2-18) Emergency Use Authorization (EUA) Request
3/4/2022
Ocugen, Inc. today announced that the U.S. Food and Drug Administration (FDA), at this time, has declined to issue an EUA for COVAXIN™ for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 2 to 18 years of age.